Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down Syndrome: Activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Down Syndrome (DS) is the most prevalent form of mental retardation caused by genetic abnormalities in humans. This has been successfully modeled in mice to generate the Ts65Dn mouse, a genetic model of DS. This transgenic mouse model shares a number of physical and functional abnormalities with people with DS, including changes in the structure and function of neuronal circuits. Significant abnormalities in noradrenergic (NE-ergic) afferents from the locus coeruleus to the hippocampus, as well as deficits in NE-ergic neurotransmission are detected in these animals. In the current study we characterized in detail the behavioral phenotype of Ts65Dn mice, in addition to using pharmacological tools for identification of target receptors mediating the learning and memory deficits observed in this model of DS. We undertook a comprehensive approach to mouse phenotyping using a battery of standard and novel tests encompassing: i) locomotion (Activity Chamber, PhenoTyper, and CatWalk), ii) learning and memory (spontaneous alternation, delayed matching-to-place water maze, fear conditioning, and Intellicage), and iii) social behavior. Ts65Dn mice showed increased locomotor activity in novel and home cage environments. There were significant and reproducible deficits in learning and memory tests including spontaneous alternation, delayed matching-to-place water maze, Intellicage place avoidance and contextual fear conditioning. Although Ts65Dn mice showed no deficit in sociability in the 3-chamber test, a marked impairment in social memory was detected. Xamoterol, a β1-adrenergic receptor (β1-ADR) agonist, effectively restored the memory deficit in contextual fear conditioning, spontaneous alternation and novel object recognition. These behavioral improvements were reversed by betaxolol, a selective β1-ADR antagonist. In conclusion, our results demonstrate that this mouse model of Down Syndrome display cognitive deficits which is mediated by imbalance in noradrenergic system. In this experimental model of Down Syndrome a selective activation of β1-ADR does restore some of these behavioral deficits. Further mechanistic studies will be needed to investigate the failure of noradrenergic system and the role of β1-ADR in cognitive deficit and pathogenesis of DS in people. Restoring NE neurotransmission or a selective activation of β1-ADR need to be further investigated for development of any potential therapeutic strategies for symptomatic relieve of memory deficit in DS. Furthermore, due to the significant involvement of noradrenergic system in the cardiovascular function further safety and translational studies will be needed to ensure the safety and efficacy of this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modality-Specific Retrograde Amnesia of Fear
Kim, J. J., & Fanselow, M. S. (1992) · Science · doi:10.1126/science.1585183 · Cited by 2,483
Moy, S. S., Nadler, J. J., Perez, A., Barbaro, R. P., Johns, J. M., Magnuson, T. R., Piven, J., & Crawley, J. N. (2004) · Genes, Brain and Behavior · doi:10.1111/j.1601-1848.2004.00076.x · Cited by 1,522 · cited 3×
“In the 3-chamber test, we found no deficits in Ts65Dn mice both in session B (test for sociability), as well as in session C (test for preference for social novelty) (Crawley, 2007; Moy et al., 2004; Moy et al., 2007).”
MethodSaxe, M. D., Battaglia, F., Wang, J.-W., Malleret, G., David, D. J., Monckton, J. E., Garcia, A. D. R., Sofroniew, M. V., Kandel, E. R., Santarelli, L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607207103 · Cited by 1,020 · cited 1×
“On the last day of the experiment, the mice were placed in Context A for 5 minutes without any conditional or unconditional stimulus {modified from the method described by (Saxe et al., 2006)}.”
MethodA mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 8×
“Extra copies of all or part of HSA21 affects a number of organs and in particular the central nervous system.”
BackgroundMethodResultInfluentialMouse behavioral tasks relevant to autism: Phenotypes of 10 inbred strains
MOY, S., NADLER, J., YOUNG, N., PEREZ, A., HOLLOWAY, L., BARBARO, R., BARBARO, J., WILSON, L., THREADGILL, D., & LAUDER, J. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.07.030 · Cited by 776
Salehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.022 · Cited by 543 · cited 4×
“In spite of significant recent progress in understanding the neurobiology of DS (Belichenko et al., 2009a; Belichenko et al., 2004; Dierssen et al., 1997; Dierssen et al., 1996; Granholm et al., 2000; Holtzman et al., 1996; Lumbreras et al., 2006; Salehi et al., 2006; Salehi et al., 2007; Salehi et al., 2009) there is…”
BackgroundInfluentialSelf-citationKleschevnikov, A. M., Belichenko, P. V., Villar, A. J., Epstein, C. J., Malenka, R. C., & Mobley, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-04.2004 · Cited by 459 · cited 3×
“This is in agreement with reported physiological abnormalities in the hippocampus of Ts65Dn mice, including reduced evoked LTP, which represents abnormal synaptic plasticity, reduced cAMP levels, and morphological changes in dendrites (Dierssen et al., 1996; Granholm et al., 2000; Kleschevnikov et al., 2004; Siarey et…”
BackgroundResultSelf-citationDevelopmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome
Holtzman, D. M., Santucci, D., Kilbridge, J., Chua-Couzens, J., Fontana, D. J., Daniels, S. E., Johnson, R. M., Chen, K., Sun, Y., Carlson, E., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13333 · Cited by 448
Self-citationSynaptic structural abnormalities in the Ts65Dn mouse model of down syndrome
Belichenko, P. V., Masliah, E., Kleschevnikov, A. M., Villar, A. J., Epstein, C. J., Salehi, A., & Mobley, W. C. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20337 · Cited by 297 · cited 6×
“Ts65Dn mice have shorter life expectancies and show morphological, neurological, and structural abnormalities that parallel those found in people with DS (Belichenko et al., 2004; Dierssen et al., 1997; Dierssen et al., 1996; Granholm et al., 2000; Holtzman et al., 1996; Lumbreras et al., 2006; Salehi et al., 2006; Sa…”
BackgroundInfluentialSelf-citationDiscovery and genetic localization of down syndrome cerebellar phenotypes using the Ts65Dn mouse
Baxter, L. L. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.2.195 · Cited by 275
Kahlem, P., Sultan, M., Herwig, R., Steinfath, M., Balzereit, D., Eppens, B., Saran, N. G., Pletcher, M. T., South, S. T., Stetten, G., et al. (2004) · Genome Research · doi:10.1101/gr.1951304 · Cited by 249 · cited 3×
“Extra copies of all or part of HSA21 affects a number of organs and in particular the central nervous system.”
BackgroundAltered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome
Siarey, R. J., Stoll, J., Rapoport, S. I., & Galdzicki, Z. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00157-3 · Cited by 222 · cited 3×
“This is in agreement with reported physiological abnormalities in the hippocampus of Ts65Dn mice, including reduced evoked LTP, which represents abnormal synaptic plasticity, reduced cAMP levels, and morphological changes in dendrites (Dierssen et al., 1996; Granholm et al., 2000; Kleschevnikov et al., 2004; Siarey et…”
BackgroundResultIncreased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome
Siarey, R. J., Carlson, E. J., Epstein, C. J., Balbo, A., Rapoport, S. I., & Galdzicki, Z. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00083-0 · Cited by 184 · cited 1×
“These changes have been demonstrated in both cellular signaling and electrophysiological studies (Dierssen et al., 1997; Dierssen et al., 1996; Kleschevnikov et al., 2004; Siarey et al., 1999; Siarey et al., 2006; Siarey et al., 1997; Siarey et al., 2005).”
BackgroundExcitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome.
Belichenko, P. V., Kleschevnikov, A. M., Masliah, E., Wu, C., Takimoto‐Kimura, R., Salehi, A., & Mobley, W. C. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21895 · Cited by 141 · cited 3×
“The T-maze had three equal arms (30 cm length, 10 cm width, and 20 cm height); the start arm and two goal arms had guillotine gates as previously described by Belichenko et al. (2009) and Deacon and Rawlins (2006) (Belichenko et al., 2009a; Deacon and Rawlins, 2006).”
BackgroundMethodResultSelf-citationHyde, L. A., Frisone, D. F., & Crnic, L. S. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00313-2 · Cited by 108 · cited 3×
“It has been shown that Ts65Dn mice have difficulty learning the context discrimination task (Hyde et al., 2001b) as well as retrieval of fear-dependent memories (Costa et al., 2008).”
BackgroundSiarey, R. J., Kline‐Burgess, A., Cho, M., Balbo, A., Best, T. K., Harashima, C., Klann, E., & Galdzicki, Z. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03971.x · Cited by 86
Cited by
Ballard, C., Mobley, W., Hardy, J., Williams, G., & Corbett, A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00063-6 · Cited by 264
Self-citationPortmann, T., Yang, M., Mao, R., Panagiotakos, G., Ellegood, J., Dolen, G., Bader, P. L., Grueter, B. A., Goold, C., Fisher, E., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.036 · Cited by 245
Self-citationXu, R., Brawner, A. T., Li, S., Liu, J.-J., Kim, H., Xue, H., Pang, Z. P., Kim, W.-Y., Hart, R. P., Liu, Y., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.04.014 · Cited by 193
Kazuki, Y., Gao, F. J., Li, Y., Moyer, A. J., Devenney, B., Hiramatsu, K., Miyagawa-Tomita, S., Abe, S., Kazuki, K., Kajitani, N., et al. (2020) · eLife · doi:10.7554/elife.56223 · Cited by 125
Treating enhanced GABAergic inhibition in Down syndrome: Use of GABA α5-selective inverse agonists
Martínez-Cué, C., Delatour, B., & Potier, M.-C. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.12.008 · Cited by 58
Metadata
- Authors
- Faizi, M., Bader, P. L., Tun, C., Encarnacion, A., Kleschevnikov, A., Belichenko, P., Saw, N., Priestley, M., Tsien, R. W., Mobley, W. C., & Shamloo, M.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 43
- Issue
- 2
- Pages
- 397-413
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2028064123
- Cited by
- 141
- References
- 16
- FWCI
- 10.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.